Tokyo Pharmaceutical announced that the key phase 3 clinical trial of urcosimod for the treatment of neurogenic corneal pain has completed the first patient enrollment.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.